AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35768092 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic blood pressure measurement (WatchBP Home A)
Number of subjects: 4339
Study 35768092 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld ECG (MyDiagnostick)
Number of subjects: 4339
Study 34600464 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline combined with tinidazole
Number of subjects: 73
Study 34600464 — intervention group
Group type: COMPARATOR
Intervention: Minocycline alone (control group)
Number of subjects: 73
Study 32183555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 139
Study 32183555 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 139
Study 32660657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein (MYC) as the primary source of dietary protein
Number of subjects: 20
Study 32660657 — intervention group
Group type: COMPARATOR
Intervention: Meat/fish (control group, CON) as the primary source of dietary protein
Number of subjects: 20
Study 32313279 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching a diabetes self-management education and support (DSMES) class
Number of subjects: 46
Study 32313279 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not teach a DSMES class)
Number of subjects: 46
Study 32955232 — intervention group
Group type: EXPERIMENTAL
Intervention: Action approach towards a child’s chronic disease
Number of subjects: 107
Study 32955232 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of parents
Number of subjects: 107
Study 32955232 — intervention group
Group type: COMPARATOR
Intervention: Place of residence of parents
Number of subjects: 107
Study 33883890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol via ELLIPTA DPI
Number of subjects: 1460
Study 33883890 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol+tiotropium
Number of subjects: 1460
Study 33035175 — intervention group
Group type: EXPERIMENTAL
Intervention: eXtreme Gradient Boosting (XGBoost) model using 8 important risk factors
Number of subjects: 123
Study 33035175 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve of the XGBoost model
Number of subjects: 123
Study 33035175 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAP and LIME algorithms for model interpretation
Number of subjects: 123
Study 35428298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (nutrition/PA)
Number of subjects: 377
Study 35428298 — intervention group
Group type: COMPARATOR
Intervention: Attention control (reading readiness/literacy)
Number of subjects: 377
Study 34550483 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles
Number of subjects: 23
Study 34550483 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin combination
Number of subjects: 23
Study 32319955 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil followed by tablet app
Number of subjects: 92
Study 32319955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet only
Number of subjects: 92
Study 32319955 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil only
Number of subjects: 92
Study 34240285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic intervention
Number of subjects: 239
Study 33464615 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized formula presented -values
Number of subjects: 0
Study 33464615 — intervention group
Group type: COMPARATOR
Intervention: LFC-based approach
Number of subjects: 0
Study 35139812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Ranibizumab (IVR) 1 or 3 days before vitrectomy
Number of subjects: 48
Study 35139812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of Ranibizumab (IVR) 3 days before vitrectomy
Number of subjects: 48
Study 35139812 — intervention group
Group type: COMPARATOR
Intervention: Sham subconjunctival injection 3 days before surgery
Number of subjects: 48
Study 34527936 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product plus usual medical care
Number of subjects: 60
Study 34527936 — intervention group
Group type: COMPARATOR
Intervention: Probiotical sham plus usual medical care
Number of subjects: 60
Study 34962062 — intervention group
Group type: EXPERIMENTAL
Intervention: Circularly polarized smartphones
Number of subjects: 120
Study 34962062 — intervention group
Group type: COMPARATOR
Intervention: Linearly polarized smartphones
Number of subjects: 120
Study 34076698 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-Initiated Clinical Trials (IICTs)
Number of subjects: 48
Study 32598904 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 99
Study 32598904 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 99
Study 35733997 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM (untreated)
Number of subjects: 24
Study 35733997 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 24
Study 35733997 — intervention group
Group type: EXPERIMENTAL
Intervention: MET (metformin therapy)
Number of subjects: 24
Study 32503663 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sargramostim 125 μg twice daily for 5 days
Number of subjects: 80
Study 32503663 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study 35665035 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional acupuncture (FA) and routine rehabilitation treatment
Number of subjects: 108
Study 35665035 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture (TA) and routine rehabilitation treatment
Number of subjects: 108
Study 33397663 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention guided by the HEARTS technical package, including training of NCD service providers, provision of essential equipment/supporting materials, and monthly monitoring and feedback.
Number of subjects: 697
Study 33397663 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline situational analysis and qualitative assessment of barriers and facilitators.
Number of subjects: 697
Study 33397663 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation monitoring and evaluation phase using the RE-AIM framework.
Number of subjects: 697
Study 35314184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative IV ketorolac (Toradol)
Number of subjects: 94
Study 35314184 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketorolac)
Number of subjects: 94
Study 33093013 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy app
Number of subjects: 40
Study 33093013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 35148732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HYAcorp Endogel)
Number of subjects: 50
Study 35148732 — intervention group
Group type: COMPARATOR
Intervention: Ovarian suspension
Number of subjects: 50
Study 34134794 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline (12 g)
Number of subjects: 9
Study 34134794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 32711655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold nanomaterial (GNP) contrast agent used in medical imaging tests
Number of subjects: 3
Study 32711655 — intervention group
Group type: COMPARATOR
Intervention: OA group (positive control)
Number of subjects: 3
Study 32711655 — intervention group
Group type: COMPARATOR
Intervention: OP group (negative control)
Number of subjects: 3
Study 36367708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean diet
Number of subjects: 36
Study 36367708 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato diet
Number of subjects: 36
Study 35942800 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 28
Study 35942800 — intervention group
Group type: COMPARATOR
Intervention: Control (CLT)
Number of subjects: 28
Study 37356077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg (single dose)
Number of subjects: 41
Study 37356077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Number of subjects: 41
Study 37356077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Number of subjects: 41
Study 33587431 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive antiviral therapy (PET)
Number of subjects: 96
Study 36124667 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly exercise
Number of subjects: 1226
Study 36124667 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo g-computation
Number of subjects: 1226
Study 36124667 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE g-computation
Number of subjects: 1226
Study 34325040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enrichment Program (CEP) - 12-week, 24-session multimodal group cognitive intervention.
Number of subjects: 37
Study 34325040 — intervention group
Group type: COMPARATOR
Intervention: Usual care in the form of individual holistic rehabilitation (active control).
Number of subjects: 37
Study 33217600 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin gel matrix (TGM), Floseal, applied at 5 mL to the pelvic sidewalls after lymphadenectomy
Number of subjects: 79
Study 33217600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TGM applied)
Number of subjects: 79
Study 36110927 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) - 60 units injected into bilateral masseter muscles
Number of subjects: 22
Study 36110927 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) - 90 units injected into bilateral masseter and temporalis muscles
Number of subjects: 22
Study 36110927 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) - 120 units injected into bilateral masseter, temporalis, and medial pterygoid muscles
Number of subjects: 22
Study 36110927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34776166 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with running training (RT) for 6 weeks, 3 sessions per week, 15 min per session, 1 kHz, 50 Hz burst frequency, 10% duty cycle.
Number of subjects: 30
Study 35608802 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary-site locoregional therapy (PSLT)
Number of subjects: 4
Study 35608802 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy (ST)
Number of subjects: 4
Study 35608802 — intervention group
Group type: EXPERIMENTAL
Intervention: PSLT
Number of subjects: 4
Study 33566072 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 316
Study 33566072 — intervention group
Group type: COMPARATOR
Intervention: Postsecondary education
Number of subjects: 316
Study 33566072 — intervention group
Group type: COMPARATOR
Intervention: Number of chronic conditions
Number of subjects: 316
Study 33566072 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 316
Study 36055537 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2.0 mA, 20 min duration, 10 sessions)
Number of subjects: 51
Study 33871713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatectomy for patients aged ≥ 80 years
Number of subjects: 579
Study 33871713 — intervention group
Group type: COMPARATOR
Intervention: Pancreatectomy for patients aged < 80 years
Number of subjects: 579
Study 32211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir + raltegravir
Number of subjects: 745
Study 32211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir + tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 745
Study 32211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase inhibitor exposure (ritonavir-boosted darunavir + raltegravir)
Number of subjects: 745
Study 32211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate exposure
Number of subjects: 745
Study 32211883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 745
Study 35613820 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded physical therapy intervention
Number of subjects: 0
Study 35613820 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32434234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of topical and intravenous tranexamic acid (TXA)
Number of subjects: 94
Study 32434234 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (TXA) alone
Number of subjects: 94
Study 32434234 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid (TXA) alone
Number of subjects: 94
Study 32434234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of IA and IV TXA
Number of subjects: 94
Study 32434234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of topical and IV TXA
Number of subjects: 94
Study 32434234 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 94
Study 35912144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 126
Study 35912144 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 126
Study 35912144 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine nursing care)
Number of subjects: 126
Study 33938413 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and self-paid COVID-19 vaccination intention
Number of subjects: 2064
Study 33938413 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in COVID-19-related work
Number of subjects: 2064
Study 32036584 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized exercise programme
Number of subjects: 66
Study 34504288 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise training (6 weeks, 3 days a week, including warm-up, trunk stabilization, and breathing exercises under physiotherapist supervision)
Number of subjects: 41
Study 34504288 — intervention group
Group type: COMPARATOR
Intervention: Control group (only informed about the importance of exercise for one session)
Number of subjects: 41
Study 33264809 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol (POST group)
Number of subjects: 144
Study 33264809 — intervention group
Group type: COMPARATOR
Intervention: Standard care (PRE group)
Number of subjects: 144
Study 35900221 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group discussions
Number of subjects: 404
Study 35900221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 404
Study 35900221 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 404
Study 35900221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 404
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion)
Number of subjects: 160
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion)
Number of subjects: 160
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus Dexmedetomidine (combination of both interventions)
Number of subjects: 160
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 160
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plus Dexmedetomidine
Number of subjects: 160
Study 33407156 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 160
Study 32500139 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE FALCON method
Number of subjects: 0
Study 34028496 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseizure medication (ASM) discontinued at discharge
Number of subjects: 303
Study 34028496 — intervention group
Group type: COMPARATOR
Intervention: Antiseizure medication (ASM) maintained at discharge
Number of subjects: 303
Study 34028496 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseizure medication (ASM) discontinued
Number of subjects: 303
Study 34028496 — intervention group
Group type: COMPARATOR
Intervention: Antiseizure medication (ASM) maintained
Number of subjects: 303
Study 33225960 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ-1a (44 mcg, three times per week for 2 weeks)
Number of subjects: 126
Study 33225960 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 126
Study 35131090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0
Study 35131090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0
Study 35131090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33755136 — intervention group
Group type: EXPERIMENTAL
Intervention: PADIT risk score (1 unit increase)
Number of subjects: 51623
Study 33755136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CIED infection
Number of subjects: 51623
Study 33755136 — intervention group
Group type: EXPERIMENTAL
Intervention: PADIT score and history of prior CIED infection
Number of subjects: 51623
Study 32139550 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (two 45 min training sessions on serrated polyp detection)
Number of subjects: 117
Study 32139550 — intervention group
Group type: COMPARATOR
Intervention: Untrained endoscopists (control group)
Number of subjects: 117
Study 32139550 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (first training session)
Number of subjects: 117
Study 32139550 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (second training session)
Number of subjects: 117
Study 33988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counselling
Number of subjects: 1364
Study 33988917 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling
Number of subjects: 1364
Study 32485945 — intervention group
Group type: COMPARATOR
Intervention: Continuous Training (CT) - 30–60 min, 70–80% peak heart rate, three times per week for eight weeks
Number of subjects: 25
Study 32485945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 5–10 near maximal 30 s sprints, 3 min recovery, three times per week for eight weeks
Number of subjects: 25
Study 34110881 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitBet (digital social game with a $30 bet for 28 days)
Number of subjects: 50
Study 34110881 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitBet (digital social game)
Number of subjects: 50
Study 34747022 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP‐SD intervention
Number of subjects: 66
Study 34747022 — intervention group
Group type: COMPARATOR
Intervention: Dummy intervention (Control)
Number of subjects: 66
Study 36242868 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cervical cerclage (ECC)
Number of subjects: 11
Study 36242868 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 11
Study 32758047 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐version of the chronic kidney disease patient awareness questionnaire
Number of subjects: 217
Study 35214712 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (three lots)
Number of subjects: 1300
Study 35214712 — intervention group
Group type: COMPARATOR
Intervention: IPV (control)
Number of subjects: 1300
Study 32404343 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab taper (every 3 weeks) for 36 weeks
Number of subjects: 122
Study 32404343 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab withdrawal (placebo) for 36 weeks
Number of subjects: 122
Study 36018230 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 978
Study 36018230 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 978
Study 32621362 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar 2 MHz radiofrequency device
Number of subjects: 19
Study 32580032 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle plus metformin
Number of subjects: 3060
Study 32580032 — intervention group
Group type: COMPARATOR
Intervention: lifestyle only
Number of subjects: 3060
Study 35040913 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 4876
Study 35040913 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4876
Study 32369630 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ decompression
Number of subjects: 117
Study 32369630 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 117
Study 35987997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender fragrance
Number of subjects: 34
Study 35987997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender)
Number of subjects: 34
Study 33504809 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ natural killer cells (NK8+) signature
Number of subjects: 0
Study 33504809 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate markers of the NK8+ signature in peripheral blood leucocytes
Number of subjects: 0
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Child victimization
Number of subjects: 385
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh punishment
Number of subjects: 385
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver depression
Number of subjects: 385
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver resilience
Number of subjects: 385
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parenting
Number of subjects: 385
Study 32758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 385
Study 36385206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (deprescribing intervention)
Number of subjects: 404
Study 36385206 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard prescribing practices)
Number of subjects: 404
Study 33958779 — intervention group
Group type: EXPERIMENTAL
Intervention: BP index variants from genome‐wide association studies (GWASs)
Number of subjects: 430